Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 97
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 to 120
Pharmaceutical / Industry
CLBH589B2201
NCT00425555
2.
Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
CLBH589B2212
NCT00490776
3.
Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
Hx-CD4-110
NCT00127881
Last Modified:
5/23/2007
4.
Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
Not specified
Other
MSKCC-95024
NCI-V95-0685, NCT00002663
Last Modified:
6/7/2006
 
First Published:
10/1/2002
5.
Phase I/II Study of Alemtuzumab-Based Conditioning Followed By HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Advanced Mycosis Fungoides/Sezary Syndrome
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 to 70
NHLBI
NHLBI-02-H-0250
NCT00047060
6.
Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
10 to 80
Other
Derm 446
NCT00129415
7.
Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI, Other
LYMNHL0014
80057, LYMNHL0014, NCT00185965, NIH, NCT00185965
Last Modified:
5/2/2007
 
First Published:
8/18/2006
8.
Phase I/II Study of Gemcitabine Hydrochloride and Pemetrexed Disodium in Patients With Advanced Mycosis Fungoides or Sézary Syndrome
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
Over 18
NCI, Pharmaceutical / Industry
NU-05H8
NU-0310-101, LILLY-NU-05H8, NCT00369629
Last Modified:
7/28/2008
 
First Published:
8/14/2007
9.
Phase I/II Randomized Pilot Study of Targeted Immune-Depleting Chemotherapy, Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation from an HLA-Matched Unrelated Donor, and Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus, Methotrexate, and Sirolimus Versus Alemtuxumab and Cyclosporine in Patients With High-Risk Advanced Hematologic Malignancies or Other Diseases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 to 69
NCI
NCI-07-C-0195
07-C-0195, NCT00520130
Last Modified:
9/29/2008
 
First Published:
2/26/2008
10.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
70 and under
Other
BCM-H-19386
BCM-FAB, H 19386, NCT00625144
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute